ReemKarmaliMD

Hematologic Oncology

Associate Professor, Division of Hematology/ Oncology, Northwestern University Feinberg School of Medicine, Robert H Lurie Cancer Center

Join to view full profile

Dr. Karmali is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Karmali's full profile

Already have an account?

Office
676 N Saint Clair St
Ste 850
Chicago, IL 60611
Phone+1 312-695-0990

Fax+1 312-695-1106

Summary

Dr. Reem Karmali is an oncologist in Chicago, IL and is affiliated with Northwestern Memorial Hospital. She received her medical degree from University of Western Ontario and has been in practice 11 years. She specializes in hematologic oncology.

Education & Training

Rush University Medical CenterFellowship, Hematology and Medical Oncology, 2012
Rush University Medical CenterResidency, Internal Medicine, 2009
University of Western OntarioClass of 2006

Certifications & Licensure

IL State Medical License 2006 - 2026
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma Start of enrollment: 2011 Sep 01
Completed
Phase 2
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 02
Terminated
Phase 3
Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies Start of enrollment: 2018 Mar 29
Completed
Phase 1, Phase 2
Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma Start of enrollment: 2018 Nov 20
Suspended
Phase 1, Phase 2
Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma Start of enrollment: 2019 Mar 13
Active, not recruiting
Phase 1
A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Start of enrollment: 2021 Nov 12
Active, not recruiting
Phase 2
Roles: Principal Investigator
Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma Start of enrollment: 2022 Mar 21
Recruiting
Phase 2
Roles: Contact, Principal Investigator
DALY II USA/ MB-CART2019.1 for DLBCL Start of enrollment: 2021 May 25
Recruiting
Phase 2
Roles: Contact
Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma Start of enrollment: 2024 Apr 24
Not yet recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

23 citations
Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investiga...
Locke J Bryan, Carla Casulo, Pamela B Allen, Scott E Smith, Hatice Savas
JAMA Oncology. 2023-05-01
91 citations
Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma.
Pamela B. Allen, Hatice Savas, Andrew M. Evens, Ranjana H. Advani, Brett Alan Palmer
Blood. 2021-03-11
27 citations
Evaluation of the impact of cachexia on clinical outcomes in aggressive lymphoma.
Madelyn Burkart, Michael Schieber, Sanjib Basu, Palmi Shah, Parameswaran Venugopal
British Journal of Haematology. 2019-04-02

Abstracts/Posters

Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma
Reem Karmali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure
Reem Karmali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas
Reem Karmali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)
Reem Karmali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
Reem Karmali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Bio-Inspired Functional Lipoprotein-like Nanoparticles (Flip-NPs) Cause Cholesterol Starvation and Ferroptosis in B-Cell Lymphomas: Studies in Cell Lines, Xenograft Mo...
Reem Karmali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Engineering CpG Deoxynucleotide-Conjugated Gold Nanoparticles for Enhanced Anti-Lymphoma Effects in an Immune Competent Lymphoma Model
Reem Karmali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
Reem Karmali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma
Reem Karmali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant
Reem Karmali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-Worl...
Reem Karmali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Brief Pembrolizumab(PEM) Monotherapy Results in Complete and Near Complete Responses in the Majority of Untreated Patients with Classical Hodgkin Lymphoma (cHL): A Mul...
Reem Karmali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classi...
Reem Karmali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Ibrutinib maintenance following induction for untreated mantle cell lymphoma (MCL): Initial safety report.
2019 ASCO Annual Meeting - 6/1/2019
Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Inhibition of Pro-Survival Pathways in DLBCL Cells By Functional Lipoprotein-like Nanoparticles
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Press Mentions

Exploring CAR T-cell Therapy for Aggressive Follicular LymphomaJuly 18th, 2024
$Confronting Knowledge Gaps Concerning Relapsed/Refractory Follicular Lymphoma$
Confronting Knowledge Gaps Concerning Relapsed/Refractory Follicular LymphomaJune 22nd, 2022
Dr. Karmali on Challenges in MCLJuly 10th, 2019
Join now to see all